Roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone

다국어 초록 (Multilingual Abstract)

Nabumetone is a prodrug, used as an anti-inflammation agent and having the active metabolite 6-methoxy-2-naphthylacetic acid (6-MNA). The role of the polymorphic enzyme responsible for the 6-O-demethylation of 6-MNA to 6-hydroxy- 2-naphtylacetic acid (6-HNA) was studied using recombinant cytochrome CYP2C9 microsomes (CYP2C9.1, CYP2C9.2 and CYP2C9.3) and human liver microsomes of known genotypes of CYP2C9. Utilizing recombinant CYP2C9.1, Vmax and Vmax/Km values of 6.3 ± 3.3 pmol/min/pmol P450 and 12.4 ± 4.7 nL/min/pmol P450, respectively, were obtained for the 6-MNA metabolism, and were almost similar to those in CYP2C9.2. In contrast, the Vmax/Km value in recombinant CYP2C9.3 was about one-third that of CYP2C9.1. In kinetic studies using liver microsomes of humans genotyped for the CYP2C9 genes, a sample genotyped as *3/*3 revealed about 4- to sixfold lower intrinsic clearance for 6-HNA formation than did samples genotyped as *1/*1. No appreciable differences were observed in kinetic parameters for 6-HNA formation in *1/*2 and *1/*3, while *2/*2 microsomes was comparable to wild type microsomes. In addition, S-warfarin 7-hydroxylation by recombinant CYP2C9.1 and CYP2C9.3 was inhibited by 6-MNA in a mixed manner. The apparent Ki value of 6-MNA on S-warfarin 7-hydroxylation by CYP2C9.3 was higher than that by CYP2C9.1. These results may provide valuable information for optimizing the anticoagulant activity of warfarin when nabumetone is co-administrated to patients.

참고문헌 (Reference)

1 Miners JO, "Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes" 10 : 267-270, 2000

2 Miners JO, "Tolbutamide hydroxylation by human liver microsomes. Kinetic characterization and relationship to other cytochrome P-450 dependent xenobiotic oxidations" 37 : 1137-1144, 1988

3 Sullivan-Klose TH, "The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism" 6 : 341-349, 1996

4 Yasar U, "The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro" 57 : 729-735, 2001

5 Rodrigues AD, "The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6(CYP2D6)" 25 : 651-655, 1997

6 Crespi CL, "The R144C change in the CYP2C9*2allele alters interaction of the cytochrome P450 with NADPH : cytochrome P450 oxidoreductase" 7 : 203-210, 1997

7 Terakawa M, "Steady-state pharmacokinetics of oral nabumetone in man" 3 : 407-416, 1988

8 Mikami E, "Simultaneous analysis of naproxen, nabumetone and its major metabolite 6-methoxy-2-naphthylacetic acid in pharmaceuticals and human urine by high-performance liquid chromatography" 23 : 917-925, 2000

9 Tsuda-Tsukamoto M, "Role of human liver cytochrome P450 2C9 in the metabolism of a novel α4β1/α4β7 dual antagonist, TR-14035" 20 : 127-134, 2005

10 Iwatsubo T, "Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data" 73 : 147-171, 1997

11 Mangan FR, "Preclinical overview of nabumetone. Pharmacology, bioavailability, metabolism, and toxicology" 83 : 6-10, 1987

12 Dennis VC, "Potentiation of oral anticoagulation and hemarthrosis associated with nabumetone" 20 : 234-239, 2000

13 Hanatani T, "No major difference in inhibitory susceptibility between CYP2C9.1 and CYP2C9.3" 59 : 233-235, 2003

14 Světlík S, "Nabumetone and 6-MNA pharmacokinetics, assessment of intrasubject variability and gender effect" 23 : 1498-1503, 2016

15 Kirchheiner J, "Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites" 13 : 473-480, 2003

16 Tang C, "In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by alleic variant forms of human liver microsomal cytochrome P450 2C9 : correlation with CYP2C9 genotype and in-vivo pharmacokinetics" 11 : 223-235, 2001

17 Jin Y, "In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharamacokinetics" 74 : 455-464, 2018

18 Yamaori S, "In vitro inhibition of CYP2C9-mediated warfarin 7-hydroxylation by iguratimod : possible mechanism of iguratimod-warfarin interaction" 38 : 441-447, 2015

19 Matsumoto K, "In vitro characterization of the cytochrome P450 isoforms involved in the metabolism of 6-methoxy-2-naphthylacetic acid, an active metabolite of the prodrug nabumetone" 34 : 734-739, 2011

20 Rettie AE, "Impaired(S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9" 4 : 39-42, 1994

21 Yamazaki H, "Human liver cytochrome P450enzymes involved in the 7-hydroxylation of R-and S-warfarin enantiomers" 54 : 1195-1203, 1997

22 Lewis DFV, "Homology modeling of human CYP2C family enzymes based on the CYP2C5 crystal structure" 32 : 305-323, 2002

23 Iwakawa S, "Effect of glimepiride and glibenclamide on S-warfarin 7-hydroxylation by human liver microsomes, recombinant human CYP2C9.1 and CYP2C9.3" 29 : 1983-1985, 2006

24 Miners JO, "Cytochrome P4502C9 : an enzyme of major importance in human drug metabolism" 45 : 525-538, 1998

25 Lee CR, "Cytochrome P450 2C9 polymorphisms : a comprehensive review of the in-vitro and human data" 12 : 251-263, 2002

26 Kirchheiner J, "Clinical consequences of cytochrome P450 2C9 polymorphisms" 77 : 1-16, 2005

27 Davies NM, "Clinical Pharmacokinetics of nabumetone. The dawn of selective cyclo-oxygenase-2 inhibition?" 33 : 403-416, 1997

28 Iida I, "Catalytic roles of CYP2C9 and its variants(CYP2C9*2 and CYP2C9*3)in lornoxicam 5′-hydroxylation" 32 : 7-9, 2004

29 Kumar V, "CYP2C9 inhibition : impact of probe selection and pharmacogenetics on in vitro inhibition profiles" 34 : 1966-1975, 2006

30 Yamaoka K, "A pharmacokinetic analysis program(multi)for microcomputer" 4 : 879-885, 1981

31 Kan T, "A book of statistical analysis for excel statistics" Esumi 2006